March 6, 2026 04:01 PM GMT China Healthcare | Asia Pacific Taking a More Even-Keeled Approach to Investment Returns in 2026 We see capital interest in our sector becoming more broad- based in 2026, compared to last year when returns were mostly generated by digital health, biotech, CDMOs, and pharmaceuticals. We reiterate WuXi AppTec (603259.SS) and Hengrui (1276.HK) as our Top Picks. Key Takeaways Investment case for China healthcare: After four consecutive years of valuation decline (2021-2024), the secto ...